Interferon hyperactivity, COVID19, and Down syndrome

干扰素过度活跃、新冠肺炎 (COVID19) 和唐氏综合症

• 批准号: 10215951
• 负责人: Joaquin M. Espinosa
• 金额: $ 61.96万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-02 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10215951
• 关键词: 2019-nCoV; Address; Administrative Supplement; Adult Respiratory Distress Syndrome; Affect; Age; Attention; Award; B-Lymphocytes; Bacterial Infections; COVID-19; Cell Lineage; Cells; Cellular Immunity; Characteristics; Chromosome 21; Clinical; Clinical Protocols; Clinical Research; Clinical assessments; Cohort Studies; Collaborations; Custom; Data; Databases; Development; Diagnosis; Diagnostic; Down Syndrome; Electronic Health Record; Ethnic Origin; Exposure to; Funding; Future; Geography; Grant; Human; Humoral Immunities; Hyperactive behavior; Immune; Immunity; Immunologics; Impairment; Incidence; Individual; Infection; Interferon Receptor; Interferons; Investigation; Knowledge; Modality; National Institute of Allergy and Infectious Disease; Parents; Participant; Pathology; Peripheral Blood Mononuclear Cell; Phenotype; Plasma; Population; Populations at Risk; Prevention; Preventive; Production; Proteome; RNA; Race; Registries; Research; Research Activity; Research Personnel; Risk; Risk Factors; Sampling; Sepsis; Series; Signal Transduction; Subgroup; Surveys; Survivors; Symptoms; T memory cell; T-Lymphocyte; Testing; Therapeutic; Tube; U-Series Cooperative Agreements; United States National Institutes of Health; Vaccines; Virus; Vulnerable Populations; Work; age difference; biobank; cellular development; cohort; coronavirus disease; cytokine; cytokine release syndrome; genome analysis; high risk; metabolome; microbiome; mouse model; neutralizing antibody; prevent; recruit; response; secondary infection; sex; transcriptome; vaccination strategy

PROJECT SUMMARY. This is an application for an Urgent Competitive Revision to our Transformative R01 award funded by the NIH INCLUDE Project and NIAID titled ‘Understanding Down Syndrome as an Interferonopathy’. The central hypothesis of the parent award is that hyperactivation of interferon (IFN) signaling causes many of the developmental and clinical hallmarks of DS. In this revision, we will investigate the interplay between IFN hyperactivity, immune dysregulation, COVID19 pathology, and immunity against SARS-CoV-2. We hypothesize that IFN hyperactivity will modify the clinical course of COVID19 in DS, including long term immunological sequalae, while potentially impairing development of cellular and humoral immunity against SARS-CoV-2. Our Specific Aims are: 1. Determine the clinical and immunological characteristics of COVID19 in DS. It is increasingly evident that individuals with DS infected by SARS-CoV-2 are more likely to be hospitalized, develop secondary bacterial infections, and die at younger ages. However, many questions remain unanswered about the clinical course of COVID19 in DS. What are the risk factors for severe COVID19 in DS? Are there treatment modalities that are less or more effective in DS? What are the sequalae of SARS-CoV-2 infection in survivors with DS? Here, we will employ the National COVID Cohort Collaborative (N3C), the DS-Connect® registry, and the Human Trisome Project (HTP) cohort study to generate a definitive assessment of the clinical and immunological characteristics of COVID19 in DS. We will complete parallel analyses of the N3C database and data obtained by the HTP team via electronic health record abstraction and participant surveys to identify differences in early symptoms, immunological parameters, clinical course, risk factors, response to different treatment modalities, and long term sequalae, with emphasis on potential differences by age, sex, race/ethnicity, and geography. 2. Investigate the immune phenotype of a cohort of COVID19 survivors with DS. Our extensive investigation of the immune phenotype of people with DS has revealed strong dysregulation of T and B cell lineages, including changes that could impair the development of cellular and humoral immunity against SARS-CoV-2 and the response to SARS-CoV-2 vaccines. Now, supported by the DS-Connect® registry and the HTP cohort study, we will obtain biospecimens from individuals with DS that survived SARS-CoV-2 infection. We will include these samples in our ongoing pan-omics characterization of IFN hyperactivity and immune dysregulation in DS, while also investigating the development and duration of memory T and B cell responses and production of neutralizing antibodies specific for SARS-CoV-2. Altogether, these synergistic aims, which address multiple aspects of this NOSI, will advance our understanding of the impacts of trisomy 21 and IFN hyperactivity on COVID19 in DS, thus informing the rapid development of customized preventive, diagnostics, and therapeutic strategies for this at-risk population.

项目摘要。 这是一份由NIH资助的对我们的变革性R 01奖进行紧急竞争性修订的申请 INCLUDE项目和NIAID题为“了解唐氏综合征作为一种干扰素病”。中央 父母奖的假设是，干扰素（IFN）信号的过度激活导致许多 DS的发展和临床特征。在本修订中，我们将研究干扰素之间的相互作用 多动、免疫失调、COVID 19病理学和针对SARS-CoV-2的免疫。我们假设 IFN过度活跃将改变DS中COVID 19的临床病程，包括长期免疫学 后遗症，而可能损害对SARS-CoV-2的细胞和体液免疫的发展。我们 具体目标是： 1.确定DS中COVID 19的临床和免疫学特征。日益明显的 感染SARS-CoV-2的DS患者更有可能住院， 感染，并在年轻时死亡。然而，许多问题仍然没有答案的临床过程中， COVID 19在DS中。DS中严重COVID 19的风险因素是什么？是否有治疗方法， 更少或更有效的DS？DS幸存者中SARS-CoV-2感染的后遗症是什么？这里我们 将采用国家COVID队列协作（N3 C），DS-Connect®登记处和人类三体 项目（HTP）队列研究，对临床和免疫学特征进行明确评估 在DS中的COVID 19。我们将完成对N3 C数据库和HTP团队获得的数据的并行分析 通过电子健康记录摘要和参与者调查来识别早期症状的差异， 免疫学参数、临床病程、风险因素、对不同治疗方式的反应以及长期 sequalae，重点是年龄、性别、种族/民族和地理的潜在差异。 2.研究患有DS的COVID 19幸存者队列的免疫表型。我们广泛的调查 DS患者的免疫表型显示了T和B细胞谱系的强烈失调，包括 这些变化可能损害抗SARS-CoV-2的细胞和体液免疫的发展， SARS-CoV-2疫苗。现在，在DS-Connect®登记研究和HTP队列研究的支持下，我们 将从SARS-CoV-2感染后存活的DS患者身上获取生物标本。我们将包括这些 在我们正在进行的泛组学特征的干扰素过度活跃和免疫失调的DS样本，而 还研究了记忆性T和B细胞应答的发展和持续时间以及中和性T细胞应答的产生。 对SARS-CoV-2有特异性的抗体。 总而言之，这些协同目标解决了NOSI的多个方面，将促进我们的理解 21三体综合征和IFN活性亢进对DS中COVID 19的影响，从而告知 为这一高危人群定制预防、诊断和治疗策略。

项目成果

Severely ill and high-risk COVID-19 patients exhibit increased peripheral circulation of CD62L+ and perforin+ T cells.

• DOI: 10.3389/fimmu.2023.1113932
• 发表时间: 2023
• 期刊: FRONTIERS IN IMMUNOLOGY
• 影响因子: 7.3
• 作者: Lesteberg, Kelsey E.;Araya, Paula;Waugh, Katherine A.;Chauhan, Lakshmi;Espinosa, Joaquin M.;Beckham, J. David
• 通讯作者: Beckham, J. David

IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome.

• DOI: 10.1016/j.celrep.2022.111883
• 发表时间: 2022-12-27
• 期刊: Cell reports
• 影响因子: 8.8

Interferon hyperactivity impairs cardiogenesis in Down syndrome via downregulation of canonical Wnt signaling.

• DOI: 10.1016/j.isci.2023.107012
• 发表时间: 2023-07-21
• 期刊: ISCIENCE
• 影响因子: 5.8
• 作者: Chi, Congwu;Knight, Walter E.;Riching, Andrew S.;Zhang, Zhen;Tatavosian, Roubina;Zhuang, Yonghua;Moldovan, Radu;Rachubinski, Angela L.;Gao, Dexiang;Xu, Hongyan;Espinosa, Joaquin M.;Song, Kunhua
• 通讯作者: Song, Kunhua

JAK inhibition for treatment of psoriatic arthritis in Down syndrome.

• DOI: 10.1093/rheumatology/keab203
• 发表时间: 2021-09-01
• 期刊: Rheumatology (Oxford, England)
• 作者: Pham AT;Rachubinski AL;Enriquez-Estrada B;Worek K;Griffith M;Espinosa JM
• 通讯作者: Espinosa JM

Plasma neurofilament light chain concentrations are elevated in youth-onset type 2 diabetes and associated with neuropathy.

青年发病的 2 型糖尿病患者血浆神经丝轻链浓度升高，并与神经病变相关。

• DOI: 10.1111/jns.12575
• 发表时间: 2023
• 期刊: Journal of the peripheral nervous system : JPNS
• 作者: Fridman,Vera;Sillau,Stefan;Ritchie,Alanna;Bockhorst,Jacob;Coughlan,Christina;Araya,Paula;Espinosa,JoaquinM;Smith,Keith;Lange,EthanM;Lange,LeslieA;Ghormli,LaureEl;Drews,KimberlyL;Zeitler,Philip;Reusch,JaneEB
• 通讯作者: Reusch,JaneEB